. "Avastin"@en . "investigational"@en . . . . "As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer."@en . "# Velcheti V, Viswanathan A, Govindan R: The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey. J Thorac Oncol. 2006 Jun;1(5):501. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17409907 # IMGT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1BJ1 # Lexicomp. Bevacizumab. N.p., 2014. Web. 11 Nov. 2014. #Bevacizumab. In DynaMed [database online]. EBSCO Information Services. http://search.ebscohost.com/login.aspx?direct=true&site=DynaMed&id=233015. Updated August 18, 2014. Accessed October 1, 2014. #Hoffmann-La Roche Limited. Bevacizumab. Mississauga, Ontario: N.p., 2014. "@en . "A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons."@en . . . . . . . . "Bevacizumab contains human framework regions with antigen binding regions of a humanised murine antibody that binds to VEGF. Bevacizumab is produced by recombinant DNA technology in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and is purified by a process that includes specific viral inactivation and removal steps. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. This prevents blood vessel proliferation and in response retardation of metastatic tumor growth occurs. "@en . "approved"@en . . . . "approximately 20 days (range: 11\u201350 days)"@en . . . . . "216974-75-3"@en . "antiVEGF"@en . . . . . "Bevacizumab"@en . " "@en . . "Humans and other mammals"@en . . "Category C in pregnancy. No studies on lactating patients: recommended to discontinue the drug or discontinue lactation. No extensive studies in pediatrics. In geriatrics: increased risk of proteinuria, arterial thromboembolic events, as well as GI bleeding and sepsis among others."@en . . "Vd: 46 mL/kg "@en . . "* 0.26 L/day [Male patients who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] * 0.21 L/day [Female patients who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] * 0.25 L/day [Patients with higher tumor burden who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] * 0.2 L/day [patients with tumor burdens below the median who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] Clearance varies by body weight, gender, and tumor burden. Increased clearance observed in men and in patients with higher tumor burden; however, no evidence of reduced efficacy."@en .